Recursion Pharmaceuticals, Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Recursion Pharmaceuticals, Inc. is one of 1613 Pharmaceuticals companies tracked from SALT LAKE CITY. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today!

Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today! Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery. We’re using data and AI to bring better medicines to patients, faster. The Recursion OS drug discovery and development platform has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. Our strategic partnerships allow us to accelerate the discovery of new medicines and expand our potential impact on patients via AI-drug discovery. This includes pharmaceutical partnerships with industry leaders, techno

Trades publicly as Pioneering AI Drug Discovery.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 99% of sector peers (real $). Modeled value above 99% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 15.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Pre-Seed$830K2015-02-17
   • First recorded raise — entered as Pre-Seed.
   • 19 investors on this round.
2. Seed$2.6M2015-11-20
   • Raised 9 mo later, in step with the ~13 mo sector norm.
   • Round 3.2× larger than the prior — scaling up.
   • 8 investors on this round.
3. Series A$4.1M2016-09-01
   • Raised 9 mo later, in step with the ~13 mo sector norm.
   • Round 1.5× larger than the prior — scaling up.
   • 31 investors on this round.
4. Series B$32.0M2016-09-01
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 7.9× larger than the prior — scaling up.
   • 32 investors on this round.
5. Series B$15.0M2016-09-02
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.1× smaller than the prior — bridge or down round.
   • 18 investors on this round.
6. Series A$12.9M2016-09-02
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 13 investors on this round.
7. Series C$55.8M2017-09-25
   • Raised 13 mo later, in step with the ~13 mo sector norm.
   • Round 4.3× larger than the prior — scaling up.
   • 26 investors on this round.
8. Series D+$122.1M2019-02-12
   • Raised 17 mo later, in step with the ~13 mo sector norm.
   • Round 2.2× larger than the prior — scaling up.
   • 33 investors on this round.
9. Series D+$245.9M2020-09-01
   • Raised 19 mo later, in step with the ~13 mo sector norm.
   • Round 2.0× larger than the prior — scaling up.
   • 49 investors on this round.
10. Series D+$235.5M2020-09-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Recursion Pharmaceuticals, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Discovered from recursion — the partnerships, launches, hiring and press it publishes about itself. Evidence the company is alive and what it is doing now, not financial data.

• FundingProgramming biology: next-gen AI firms raise billions to design better medicines2026-05-26
• UpdatePatient advocate offers Recursion a powerful reason to keep going in rare disease2026-04-29
• UpdateThe Quest to Use AI to Help Find New Drugs2026-04-04
• UpdateRecursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers2026-03-19
• UpdateADMET Predictions Get AI Boost, Federated Data Network Unites Pharma2026-02-25
• HiringSF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech2026-01-15
• UpdateRecursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial2025-12-08
• UpdateRecursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points2025-12-01
• Update2025's Fiercest Women in Life Sciences2025-11-17
• UpdateAI medicines are coming2025-09-11
• UpdateWhy Is AI Struggling to Design New Drugs?2025-09-10
• UpdateRising Leaders 2025: Daniel Cohen’s Transition From Grad To AI Pioneer In Drug Discovery2025-09-03

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Recursion Pharmaceuticals, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Recursion Pharmaceuticals, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.